Topic: inhaled drug delivery
Novartis showed the combination is better at improving lung function than an ICS alone, giving it a boost as it heads toward an approval decision.
Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.
Roivant Sciences’ spinout machine keeps turning with the launch of the lung-focused Respivant Sciences, with tech and staff from Patara Pharma.
Vectura showed in two phase 2 studies that children with asthma can use its nebulized inhaler, as it aims to reduce delivery times and steroid doses.
Propeller Health and Aptar Pharma partner up to digitize drug delivery and offer a platform for pharma companies to track and manage patient usage.
Just days after their lead drug-device combination was voted down by FDA advisors, Nektar and Bayer were hit by a phase 3 failure in another program.
The move represents a big win for Propeller Health, which has a chance to provide its sensor-enabled inhaler and app to a large group of patients.
Engage Therapeutics raised $23 million for its EpiPen-like rescue treatment for epileptic seizures.
Genoa Pharmaceuticals has raised $62 million to take its lead candidate into the clinic.
Boehringer Ingelheim Pharmaceuticals and Qualcomm subsidiary Qualcomm Life have partnered on the Respimat inhaler.